588 related articles for article (PubMed ID: 27324387)
21. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
22. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
23. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
Costa LJ; Feldman AL; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
Br J Haematol; 2008 Jul; 142(3):404-12. PubMed ID: 18492096
[TBL] [Abstract][Full Text] [Related]
24. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
[TBL] [Abstract][Full Text] [Related]
27. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients.
Shin HJ; Yoon DH; Lee HS; Oh SY; Yang DH; Kang HJ; Chong SY; Park Y; Do Y; Lim SN; Jo JC; Lee WS; Chung JS;
Exp Hematol; 2016 Jan; 44(1):3-13. PubMed ID: 26325332
[TBL] [Abstract][Full Text] [Related]
28. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
29. Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis.
Ma SY; Tian XP; Cai J; Zhong GZ; Chen X; Huang HQ; Lin TY; Li ZM; Cai QQ
Ann Hematol; 2020 Jun; 99(6):1311-1319. PubMed ID: 32285160
[TBL] [Abstract][Full Text] [Related]
30. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
[TBL] [Abstract][Full Text] [Related]
31. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
Gaut D; Romero T; Oveisi D; Howell G; Schiller G
Hematol Oncol; 2020 Feb; 38(1):38-50. PubMed ID: 31674036
[TBL] [Abstract][Full Text] [Related]
32. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
[TBL] [Abstract][Full Text] [Related]
34. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
Kagami Y; Yamamoto K; Shibata T; Tobinai K; Imaizumi Y; Uchida T; Shimada K; Minauchi K; Fukuhara N; Kobayashi H; Yamauchi N; Tsujimura H; Hangaishi A; Tominaga R; Suehiro Y; Yoshida S; Inoue Y; Suzuki S; Tokuhira M; Kusumoto S; Kuroda J; Yakushijin Y; Takamatsu Y; Kubota Y; Nosaka K; Morishima S; Nakamura S; Ogura M; Maruyama D; Hotta T; Morishima Y; Tsukasaki K; Nagai H
Cancer Sci; 2020 Oct; 111(10):3770-3779. PubMed ID: 32767806
[TBL] [Abstract][Full Text] [Related]
35. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
[TBL] [Abstract][Full Text] [Related]
36. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
37. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.
Calvo-Villas JM; Martín A; Conde E; Pascual A; Heras I; Varela R; de la Rubia J; Ramirez MJ; Díez-Martín JL; Panizo C; Rodríguez-Salazar MJ; Pascual MJ; Donato EM; González-Barca E; Caballero MD;
Ann Oncol; 2010 Sep; 21(9):1891-1897. PubMed ID: 20231299
[TBL] [Abstract][Full Text] [Related]
38. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
[TBL] [Abstract][Full Text] [Related]
39. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
40. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
Li M; Liu CL; Wang XY; Xue XM; Gao ZF
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
